07:00 , May 5, 2014 |  BioCentury  |  Product Development

Targeted cargo

Taiwan Liposome Co. Ltd. and Ablynx N.V. are investigating whether combining their technologies can yield next-generation antibody-drug conjugates that deliver more molecules more precisely than existing ADC technologies. TLC manufactures liposomal formulations of the generic drugs...
07:00 , Sep 26, 2011 |  BioCentury  |  Product Development

Slow is good

Nektar Therapeutics now has proof of mechanism for its small molecule polymer conjugates in a new therapeutic area: pain. Last week, the company presented Phase I data showing its novel mu opioid receptor agonist construct...
07:00 , Jun 21, 2010 |  BioCentury  |  Product Development

Targeting ovarian

Successes with targeted therapies in solid tumors such as colon, breast and lung cancers have led several companies to explore targeted treatment approaches in ovarian cancer, including antiangiogenics and ligand-targeted chemotherapeutics. Presentations at this year's...
07:00 , Sep 28, 2009 |  BioCentury  |  Strategy

Nektar's Next Step

Nektar Therapeutics had expected to become profitable in mid-2007 based on royalties from Exubera inhaled insulin. Instead, partner Pfizer Inc. terminated the diabetes drug from its portfolio that October because it failed to gain acceptance...
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

Advanced Polymer sales and marketing update

APOS partner Dermik Laboratories Inc., a subsidiary of Aventis S.A. (AVE, Strasbourg, France), launched APOS's Carac Microsponge formulation of 5-FU to treat actinic keratoses. APOS will receive royalties. Advanced Polymer Systems Inc. (APOS),...
08:00 , Nov 6, 2000 |  BC Week In Review  |  Clinical News

Microsponge formulation of 5-fluorouracil regulatory update

The FDA granted marketing approval for the company's Microsponge formulation of 5-FU to treat actinic keratoses. Dermik Laboratories Inc., a subsidiary of Aventis S.A. (AVE, Strasbourg, France), will market the product in the U.S....
08:00 , Nov 6, 2000 |  BioCentury  |  Finance

Shifting demand

As investors seem sated by the IPO buffet, demand has shifted to PIPEs and follow-ons for later-stage publicly held companies. Nine NASDAQ-listed biotechs raised more than $1 billion in six PIPE deals and three follow-ons...
08:00 , Oct 30, 2000 |  BC Extra  |  Company News

Advanced Polymer gets 5-fluorouracil approval

APOS received FDA marketing approval for a 5-fluorouracil formulation using its Microsponge delivery technology to treat actinic keratoses. Dermik Laboratories, a subsidiary of Aventis (AVE), will market the product in the U.S....
07:00 , Aug 7, 2000 |  BC Week In Review  |  Company News

Advanced Polymer management update

Advanced Polymer Systems Inc. (APOS), Redwood City, Calif.   Business: Drug delivery   Promoted: Gordon Sangster to CFO from VP of finance and controller; and John Barr to VP of R&D from director of pharmaceutical sciences   ...
07:00 , Jul 31, 2000 |  BC Week In Review  |  Company News

Advanced Polymer, R.P. Scherer deal

APOS completed the previously announced sale of its cosmeceutical business and certain rights to its Microsponge and Polytrap delivery technologies to Scherer, a subsidiary of Cardinal Health Inc. (CAH, Dublin, Ohio) (see BioCentury, June...